Related references
Note: Only part of the references are listed.Diversity and versatility of p38 kinase signalling in health and disease
Begona Canovas et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2021)
Calcium-dependent methylation by PRMT1 promotes erythroid differentiation through the p38α MAPK pathway
Mei-Yin Liu et al.
FEBS LETTERS (2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
The MKK-Dependent Phosphorylation of p38α Is Augmented by Arginine Methylation on Arg49/Arg149 during Erythroid Differentiation
Mei-Yin Liu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis
Claudia Vener et al.
BLOOD ADVANCES (2020)
Combination therapy in combating cancer
Reza Bayat Mokhtari et al.
ONCOTARGET (2017)
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Aravind Subramanian et al.
CELL (2017)
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
Bing Z. Carter et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
Derrick M. Oaxaca et al.
TUMOR BIOLOGY (2016)
H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib
Yaqiong Dong et al.
APOPTOSIS (2014)
Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
Alexander M. Menzies et al.
CLINICAL CANCER RESEARCH (2014)
The Leukemias: A Half-Century of Discovery
Emil J. Freireich et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Role of MET Receptor Tyrosine Kinase in Non-Small Cell Lung Cancer and Clinical Development of Targeted Anti-MET Agents
Kyle W. Robinson et al.
ONCOLOGIST (2013)
Protein Arginine Methyltransferase 1 Interacts with and Activates p38α to Facilitate Erythroid Differentiation
Wei-Kai Hua et al.
PLOS ONE (2013)
Management of imatinib-resistant patients with chronic myeloid leukemia
Pavan Kumar Bhamidipati et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)
Treatments for chronic myeloid leukemia: a qualitative systematic review
Roxanne Ferdinand et al.
JOURNAL OF BLOOD MEDICINE (2012)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
Mechanisms and functions of p38 MAPK signalling
Ana Cuadrado et al.
BIOCHEMICAL JOURNAL (2010)
Pathological roles of MAPK signaling pathways in human diseases
Eun Kyung Kim et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2010)
Protein-arginine Methyltransferase 1 Suppresses Megakaryocytic Differentiation via Modulation of the p38 MAPK Pathway in K562 Cells
Yuan-I Chang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review
Xin An et al.
LEUKEMIA RESEARCH (2010)
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
William Pao et al.
NATURE REVIEWS CANCER (2010)
Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib
Disha Dumka et al.
LEUKEMIA & LYMPHOMA (2009)
Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis
Neil P. Shah et al.
CANCER CELL (2008)
Flying under the radar:: the new wave of BCR-ABL inhibitors
Alfonso Quintas-Cardama et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
P38 MAP-Kinases pathway regulation, function and role in human diseases
Ana Cuenda et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
Ellen Weisberg et al.
NATURE REVIEWS CANCER (2007)
Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition
A. Jacquel et al.
ONCOGENE (2007)
Important therapeutic targets in chronic myelogenous leukemia
Hagop M. Kantarjian et al.
CLINICAL CANCER RESEARCH (2007)
Novel inhibitor of p38 MAP kinase as an anti-TNF-α drug:: Discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent
S Miwatashi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells
K Kohmura et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2004)
Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells
S Parmar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Share Paper
